Zenas BioPharma Earnings Call Transcripts
Fiscal Year 2026
-
The summit showcased a strong pipeline with obexelimab nearing commercialization for IgG4-RD, supported by positive phase III data and strong market interest. Orelabrutinib and other neuro candidates are advancing in late-stage trials, with several key data readouts and regulatory milestones expected in the next year.
-
The meeting confirmed a quorum and saw the election of two directors and ratification of the auditor for 2026. No additional shareholder proposals were introduced, and final voting results will be disclosed in a forthcoming Form 8-K.
-
Obexelimab demonstrated strong efficacy and safety in IgG4-RD, with high physician and patient preference for its inhibitory, subcutaneous approach. Commercial launch is planned for the US and Europe, with a robust pipeline advancing in lupus, MS, and psoriasis.
-
Obexelimab achieved a 56% reduction in IgG4-RD flare risk versus placebo in the phase III INDIGO trial, meeting all primary and key secondary endpoints with a strong safety profile and over 70% of patients protected from flare. The drug's unique mechanism, at-home administration, and favorable tolerability position it as a potential first-line therapy.
Fiscal Year 2025
-
Major clinical milestones included phase III completion for obexelimab in IgG4-RD, strong phase II results in RMS, and ongoing lupus studies. Strategic deals expanded the pipeline and secured $300M in financing. Market opportunity in IgG4-RD is sizable, with product differentiation focused on at-home dosing and non-depleting B-cell inhibition.
-
The conference highlighted a robust pipeline with major upcoming milestones, including year-end phase III results for obexelimab in IgG4-RD and strong phase II MS data. Rilzabrutinib is advancing in progressive MS, and early-stage programs are set for phase I in 2025.
-
Announced a global collaboration to acquire orelabrutinib and expand the autoimmune pipeline, with multiple late-stage and next-gen assets targeting significant commercial opportunities. Orelabrutinib's phase III MS trials are underway, and key data readouts for obexelimab and other programs are expected within the next year.
-
Obexelimab is advancing through pivotal trials in IgG4-related disease, MS, and SLE, with a focus on at-home subcutaneous administration and continuous dosing for improved outcomes. Key data readouts are expected over the next year, supported by strong capital and strategic partnerships.
-
Obexelimab is nearing a pivotal phase III readout in IgG4-related disease, with additional phase II trials in MS and SLE progressing. A $300M Royalty Pharma deal extends the cash runway and validates the market opportunity, while at-home dosing and a differentiated safety profile position the product competitively.
-
Obexelimab is advancing in three autoimmune indications, with phase 3 IgG4RD data expected year-end, phase 2 RMS data in early Q4, and lupus phase 2 data mid-next year. A $300M Royalty Pharma deal secures funding through Q1 2027 and validates the program's potential.
-
Three pivotal data readouts are expected over the next year for IgG4-related disease, MS, and lupus, with Obexelimab positioned as a differentiated, convenient B cell inhibitor. The company is well-funded, preparing for commercialization, and exploring additional indications.
-
Obexelimab, a novel B cell inhibitor, is advancing through phase II and III trials in multiple autoimmune diseases, with key data readouts expected in MS (Q3), IgG4-RD (year-end), and SLE (next year). The approach offers potential safety, efficacy, and convenience advantages over current therapies.
Fiscal Year 2024
-
The platform is advancing Obexelimab in autoimmune diseases, with phase 3 IgG4-RD and phase 2 MS and lupus trials underway. Obexelimab offers rapid, sustained B-cell inhibition with convenient at-home dosing, differentiating it from competitors. Top-line data for MS and IgG4-RD are expected in 2025, with lupus results in 2026, and the company is well-funded through these milestones.
-
Obexelimab, a differentiated B cell inhibitor, is advancing through global phase III and II trials in IgG4-RD, RMS, and SLE, with key data readouts expected from late 2025 through 2026. The company targets a $3B market opportunity with a convenient at-home dosing regimen.